CE2023-06-21T12:00:43
An FDA-approved anti-inflammatory drug can reduce cardiovascular disease risk by an additional 31 percent in adults, on top of standard of care, clinical data has shown.
Already a member? Sign-in
European Pharmaceutical Review delivers authoritative insights, cutting-edge innovations, and expert perspectives that not only inform decisions but drive measurable progress across quality, compliance, and operational excellence.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-02-25T15:00:00
Sponsored by Particle Measuring Systems
2026-10-27T10:14:00
Sponsored by Capsugel
2026-06-10T15:00:00
Sponsored by BioDuro
2026-06-15T07:55:00
Sponsored by Octave, Adam Cross
Site powered by Webvision Cloud